Eli Lilly and Co (NYSE:LLY)
$ 775 -2.77 (-0.36%) Market Cap: 736.56 Bil Enterprise Value: 762.62 Bil PE Ratio: 116.09 PB Ratio: 57.49 GF Score: 81/100

Q1 2020 Eli Lilly and Co Earnings Call Transcript

Apr 23, 2020 / 01:00PM GMT
Release Date Price: $159.93 (+2.05%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Lilly Q1 earnings conference call. (Operator Instructions) As a reminder, your conference call today is being recorded. I will now turn the conference call over to your host, Vice President of Investor Relations, Kevin Hern. Go ahead, please.

Kevin Hern
Eli Lilly and Company - VP of IR

Good morning. Thank you for joining us for Eli Lilly and Company's Q1 2020 Earnings Call. I'm Kevin Hern, Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chairman and CEO; Josh Smiley, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific Officer; Anne White, President of Lilly Oncology; Patrik Jonsson, President of Lilly Bio-Medicines; and Mike Mason, President of Lilly Diabetes. We're also joined by Sara Smith and Mike Czapar of the Investor Relations team.

In addition, I would like to welcome Anat Hakim, who recently joined Lilly as Senior Vice President and General Counsel. Anat joins Lilly with a wealth of experience in the health care industry, and more

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot